Evidence map›Paper›PMID 41008938›Full record

ArticleAntioxidants (Basel, Switzerland)2025

Manganese Porphyrin Reduces Oxidative Stress in Vulnerable Parkin-Null

Amber N Juba, Petros P Keoseyan, Riley P Hamel, Tigran Margaryan, Michaela L Barber, Amanda N Foley, T Bucky Jones, Ines Batinic-Haberle, Artak Tovmasyan, Lori M Buhlman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Amber N JubaBiomedical Sciences Program, Midwestern University, Glendale, AZ 85308, USA.ORCID 0000-0002-3782-8560
Petros P KeoseyanArizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.
Riley P HamelArizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.
Tigran MargaryanDepartment of Translational Neuroscience, Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ 85013, USA.
Michaela L BarberBiomedical Sciences Program, Midwestern University, Glendale, AZ 85308, USA.
Amanda N FoleyArizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.
T Bucky JonesArizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.
Ines Batinic-HaberleDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0001-8037-1861
Artak TovmasyanDepartment of Translational Neuroscience, Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ 85013, USA.ORCID 0000-0002-8612-1676
Lori M BuhlmanBiomedical Sciences Program, Midwestern University, Glendale, AZ 85308, USA.ORCID 0000-0002-2987-839X

Funding

Ivy Foundation NAMidwestern University NA
6 · The paper itself

Abstract

Oxidative stress and mitochondrial dysfunction are heavily implicated in all forms of Parkinson's disease; however, antioxidant administration has largely failed in clinical trials. Among the likely causes of failure are brain bioavailability and cellular redox state. We have administered two manganese porphyrin compounds with different bioavailability, MnTE-2-PyP

Indexed as

antioxidantsdopaminergic neuronDrosophilaglutathionehydrogen peroxidemanganese porphyrinmitochondriaoxidative stressparkinredox

Identifiers

PMID41008938
PMCPMC12466752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.